Huimin Liu
Research Subjects
Research Interests
Huimin Liu has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Shouxin Wu
Biotecan Medical Diagnostics Co., Ltd., Zhangjiang Center for Translational Medicine, Shanghai 201203, P.R. China
3 shared publicationsAihua Luo
Department of Radiotherapy and Chemotherapy, The Second People's Hospital, Three Gorges University, Yichang, Hubei 443002, P.R. China
1 shared publication- Binhui Yang
Department of Oncological Surgery
1 shared publication Fei Deng
Department of Radiotherapy and Chemotherapy, The Second People's Hospital, Three Gorges University, Yichang, Hubei 443002, P.R. China
1 shared publicationHaotian Wu
Biotecan Medical Diagnostics Co., Ltd., Zhangjiang Center for Translational Medicine, Shanghai 201203, China
1 shared publicationJiangman Zhao
Biotecan Medical Diagnostics Co., Ltd., Zhangjiang Center for Translational Medicine, Shanghai 201203, China
1 shared publication
Latest Publications
- Open Access
- 3 February 2021
- Published by Spandidos Publications in Oncology Letters
- Vol. 21 (4) , 1
MicroRNA‑429 acts as a tumor suppressor in colorectal cancer by targeting high mobility group box 3
Colorectal cancer (CRC) is one of the most common solid tumors worldwide and has an extremely poor prognosis. MicroRNA‑429 (miR‑429) has been reported to participate in the progression of CRC. However, the pathological mechanisms require further investigation. The aim of the present study was to investigate the association between miR‑429 and high mobility group box 3 (HMGB3) in CRC and the associated mechanism. The mRNA expression levels of miR‑429 and HMGB3 in 65 paired CRC and adjacent tissues were examined by reverse transcription‑quantitative PCR. Furthermore, a dual‑luciferase reporter assay was performed to identify the association between miR‑429 and HMGB3. Finally, the effects of miR‑429 and HMGB3 on the proliferation and apoptosis of CRC cells were detected. As a result, it was identified that miR‑429 expression was downregulated and HMGB3 expression was upregulated in CRC tissues compared with in adjacent non‑cancer tissues, and the expression levels of miR‑429 were negatively associated with those of HMGB3. Notably, HMGB3 was demonstrated to be a direct target of miR‑429 by dual‑luciferase reporter assay. Furthermore, transfection with a miR‑429 mimic significantly inhibited HMGB3 expression and led to decreased proliferation and increased apoptosis of CRC cells. On the other hand, transient overexpression of HMGB3 partially inhibited the antitumor effects of miR‑429. To the best of our knowledge, the present study demonstrated for the first time that miR‑429 regulated the proliferation and apoptosis of CRC cells via HMGB3, suggesting a specific tumor suppressive function of the miR‑429/HMGB3 signaling pathway in CRC.
- 3 February 2021
- Published by Spandidos Publications in Oncology Letters
- Vol. 21 (4) , 1
Open AccessMicroRNA‑429 acts as a tumor suppressor in colorectal cancer by targeting high mobility group box 3
Colorectal cancer (CRC) is one of the most common solid tumors worldwide and has an extremely poor prognosis. MicroRNA‑429 (miR‑429) has been reported to participate in the progression of CRC. However, the pathological mechanisms require further investigation. The aim of the present study was to investigate the association between miR‑429 and high mobility group box 3 (HMGB3) in CRC and the associated mechanism. The mRNA expression levels of miR‑429 and HMGB3 in 65 paired CRC and adjacent tissues were examined by reverse transcription‑quantitative PCR. Furthermore, a dual‑luciferase reporter assay was performed to identify the association between miR‑429 and HMGB3. Finally, the effects of miR‑429 and HMGB3 on the proliferation and apoptosis of CRC cells were detected. As a result, it was identified that miR‑429 expression was downregulated and HMGB3 expression was upregulated in CRC tissues compared with in adjacent non‑cancer tissues, and the expression levels of miR‑429 were negatively associated with those of HMGB3. Notably, HMGB3 was demonstrated to be a direct target of miR‑429 by dual‑luciferase reporter assay. Furthermore, transfection with a miR‑429 mimic significantly inhibited HMGB3 expression and led to decreased proliferation and increased apoptosis of CRC cells. On the other hand, transient overexpression of HMGB3 partially inhibited the antitumor effects of miR‑429. To the best of our knowledge, the present study demonstrated for the first time that miR‑429 regulated the proliferation and apoptosis of CRC cells via HMGB3, suggesting a specific tumor suppressive function of the miR‑429/HMGB3 signaling pathway in CRC.
- Open Access
- 1 February 2020
- Published by Elsevier in Translational Oncology
- Vol. 13 (2) , 245-253
Genetic Profiling of Breast Cancer with and Without Preexisting Metabolic Disease
- 1 February 2020
- Published by Elsevier in Translational Oncology
- Vol. 13 (2) , 245-253
Open AccessGenetic Profiling of Breast Cancer with and Without Preexisting Metabolic Disease
- Open Access
- 5 July 2019
- Published by Spandidos Publications in Oncology Letters
- Vol. 18 (3) , 2619-2627
Whole exome sequencing study of a Chinese concurrent cancer family
Cancer is one of the leading causes of mortality in China, and poses a threat to public health due to its increasing incidence and mortality rates. Concurrent cancer is defined as one or more organs in the same individual having ≥2 primary malignancies occurring simultaneously or successively; however, concurrent cases are rare and poorly studied. The present study recruited a Chinese family presenting multiple cases of concurrent cancer and performed whole exome sequencing in one unaffected and two affected individuals to identify the causative mutations. DNA was extracted from peripheral blood and tumor tissue samples. Following an exome capture and quality test, the qualified library was sequenced as 100 bp paired‑end reads on an Ion Torrent platform. Clean data were obtained by filtering out the low‑quality reads. Subsequently, bioinformatics analyses were performed using the clean data. After mapping and annotating in 1000 Genomes Project database, the existing SNP database and the Cancer Gene Census (CGC) database, it was revealed that the NADH:ubiquinone oxidoreductase core subunit S7 gene was a candidate gene with somatic mutations, and a subset of 16 genes were candidate genes with germline mutations. The findings of the present study may improve the understanding of the molecular pathogenesis of concurrent cancer.
- 5 July 2019
- Published by Spandidos Publications in Oncology Letters
- Vol. 18 (3) , 2619-2627
Open AccessWhole exome sequencing study of a Chinese concurrent cancer family
Cancer is one of the leading causes of mortality in China, and poses a threat to public health due to its increasing incidence and mortality rates. Concurrent cancer is defined as one or more organs in the same individual having ≥2 primary malignancies occurring simultaneously or successively; however, concurrent cases are rare and poorly studied. The present study recruited a Chinese family presenting multiple cases of concurrent cancer and performed whole exome sequencing in one unaffected and two affected individuals to identify the causative mutations. DNA was extracted from peripheral blood and tumor tissue samples. Following an exome capture and quality test, the qualified library was sequenced as 100 bp paired‑end reads on an Ion Torrent platform. Clean data were obtained by filtering out the low‑quality reads. Subsequently, bioinformatics analyses were performed using the clean data. After mapping and annotating in 1000 Genomes Project database, the existing SNP database and the Cancer Gene Census (CGC) database, it was revealed that the NADH:ubiquinone oxidoreductase core subunit S7 gene was a candidate gene with somatic mutations, and a subset of 16 genes were candidate genes with germline mutations. The findings of the present study may improve the understanding of the molecular pathogenesis of concurrent cancer.